Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported first quarter 2021 financial results along with a general business update.

“We continue our dedication to help save lives from COVID-19 by bringing COVAXIN to the U.S. market while simultaneously driving our ophthalmology gene therapy pipeline toward the clinic. We shared compelling second interim analysis results of Bharat Biotech’s Phase 3 clinical trial in India as well as positive data from in-vitro studies regarding COVAXIN’s ability to neutralize emerging variants. We continue to make progress toward Emergency Use Authorization for COVAXIN while also considering clinical development in special populations, such as children, as well as booster doses. We are delighted to have raised additional capital to fund our ongoing and future operations and to allow us to recruit key talent during this important stage of our growth,”  said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.

• COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization)
• Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorization application for COVAXIN
• $100.0  million in gross proceeds raised through a registered direct offering of common stock
• Key talent acquired representing an instrumental step to position Ocugen for future growth

First Quarter 2021 Financial Results

• Ocugen’s cash, cash equivalents, and restricted cash totaled $44.9  million as of March  31, 2021, compared to $24.2  million as of December  31, 2020. Ocugen had 188.2  million shares of common stock outstanding as of March  31, 2021.
• Research and development expenses for the three months ended March 31, 2021 were $2.9  million compared to $1.7  million for the three months ended March 31, 2020. General and administrative expenses for the three months ended March 31, 2021 were $4.2  million compared to $2.3  million for the three months ended March 31, 2020. Ocugen reported a $0.04 net loss per share for the three months ended March 31, 2021 compared to a $0.07 net loss per share for the three months ended March 31, 2020.

CWEB Analyst’s have initiated a BUY Rating for   Ocugen, Inc. (NASDAQ: OCGN) and potential upside of $11 in 2021. The fundamentals of the company are to strong and cash on hand has increased compare to previous quarter. We believe Q3 will be the real break for the company and increase of revenue.